SIGNIFICANT ROLE OF NF-KB, NF-AT, ANNEXIN A5 AND TRAIL IN IRAQI FEMALE WITH BREAST CANCER

Mays Najem Al-Adilee; Hazima Mossa ALabassi

doi:10.46903/gjms/23.1.1866

SIGNIFICANT ROLE OF NF-KB, NF-AT, ANNEXIN A5 AND TRAIL IN IRAQI FEMALE WITH BREAST CANCER

Mays Najem Al-Adilee, Hazima Mossa ALabassi

Abstract

Background: Breast cancer is a common cancer in women and especially in developing countries the incidence rates of this cancer are rising, including Iraq. There is need to identify the molecular basis of the disease and its progression with a view of discovering better treatment regimens. This study aimed to investigate the role of NF-KB, NF-ATc1, Annexin A5 and TRAIL in pathogenicity of breast cancer in order to detect a new therapeutic target.

Materials & Methods: A pilot study was carried out on samples at Iraqi women with breast cancer in hospitals of Baghdad during the period from August 2023 until December 2023. A total of 88 blood samples were collected (60 blood samples which included 30 samples for newly diagnosed patients and 30 samples for patients under treatment with chemotherapy (Adriamycin and cyclophosphamide) at a dos-age of (60mg/M2) with age range 25-65 years, in addition to 28 blood samples for apparently healthy women serve as control group with age range match to patients group. The current research focuses on the real participation of NF-κB, NFATc1, ANXA5, and TRAIL in the progression among the Iraqi women with Breast cancer. Expression of NF-κB and NFATc1 was determined by quantitative PCR. AnnexinA5 and TRAIL levels were determined by ELISA technique. The findings confirmed that NF-κB and NFATc1 are over expressed in newly diagnosed breast cancer patients compared with the control and under treatment patients suggesting their implication in tumor advancement.

Results: It was observed that serum Annexin A5 and TRAIL levels were higher in newly diagnosis patients and a significant lowering of all the parameters was noted under treatment thus establishing the efficacy of the treatment strategies. It was also found that NF-κB and NFATc1 genes are co-regulated because of their positive correlation, r=0. 668, p=0. 001. However, no correlation was observed between the gene expression of NF-κB or NFATc1 and serum levels of AnnexinA5 or TRAIL, indicating distinct regulatory mechanisms. These findings underscore the importance of NF-κB and NFATc1 as potential therapeutic targets, while the reduction of all markers under treatment highlights the efficacy of current interventions.

Conclusion: In conclusion, targeting these molecular pathways could offer new therapeutic strategies for improving breast cancer outcomes, particularly in Iraqi women.

Keywords

Cancer; Breast cancer; NF-KB; NF-AT; Annexin A5; TRAIL; Gene expression; ELISA.

Full Text:

PDF

References

Almohaidi AMS, Al-Abassi HM, Abdulkareem ZJ, Al-Sayyid MM. Sera level and polymorphism of interleukin-33 gene in Iraqi females patients with breast cancer. Ibn AL-Haitham J Pure Appl Sci. 2021;34:1-11. https://doi.org/10.30526/34.1.2806

Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The nuclear factor kappa B (NF-κB) signaling in cancer development and immune diseases. Genes Dis. 2021;8:287-97. https://doi.org/10.1016/j.gendis.2020.06.005

Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R. NF-κB: at the borders of autoimmunity and inflammation. Front Immunol. 2021;12:1-27. https://doi.org/10.3389/fimmu.2021.716469

Salman AO, Al-Abassi HM, Mahod WS. Demographic and clinico-pathological characteristics of some Iraqi female patients newly diagnosed with breast cancer. Ann Roman Soc Cell Biol. 2021;25:8264-78. http://annalsofrscb.ro/index.php/journal/article/view/7018

Zhang T, Ma C, Zhang Z, Zhang H, Hu H. NF-κB signaling in inflammation and cancer. Med Comm. 2021;2:618-53. https://doi.org/10.1002/mco2.104

Ali HK, Mahood WS. Expression of transketolase TKTL1 in Iraqi breast cancer females. J Popul Therap Clin Pharmacol. 2023;30:55-61. https://doi.org/10.47750/jptcp.2023.30.08.006

M-Amen K, Abdullah OS, Amin AMS, Mohamed ZA, Hasan B, Shekha M, et al. Cancer incidence in the Kurdistan region of Iraq: results of a seven-year cancer registration in Erbil and Duhok governorates. Asian Pac J Cancer Prev. 2022;23(2):601-15. https://doi.org/10.31557/APJCP.2022.23.2.601

Dare AJ, Knapp GC, Romanoff A, Olasehinde O, Famurewa OC, Komolafe AO, et al. High-burden cancers in middle-income countries: a review of prevention and early detection strategies targeting at-risk populations. Cancer Prev Res (Phila). 2021;14(12):1061-74. https://doi.org/10.1158/1940-6207.CAPR-20-0571

Alrawi N. A review on breast cancer in Iraq and future therapies insights. Baghdad J Biochem Appl Biol Sci. 2022;3:4-16. https://doi.org/10.47419/bjbabs.v3i01.64

Alkashaf KH, Mohammed SI. Impact of clinical pharmacist intervention on chemotherapy knowledge, attitude, and practice among breast cancer women. J Fac Med Baghdad. 2024;66:103-9. https://doi.org/10.47419/bjbabs.v3i01.64

Abdullah MR, Alabassi HM. The potential influence of immune modulatory molecules (TGF-βIII and CTLA-4) in pathogenicity of PCOS. Karbala Int J Mod Sci. 2024;10(2):363-75. https://doi.org/10.33640/2405-609X.3361

Hashim HT, Ramadhan MA, Theban KM, Bchara J, El-Abed-El-Rassoul A, Shah J. Assessment of breast cancer risk among Iraqi women in 2019. BMC Womens Health. 2021;21:1-9. https://doi.org/10.1186/s12905-021-01557-1

Abbas MM, Alkhazrajy LA. Knowledge, attitudes and practices regarding the screening of colorectal cancer among primary care physicians in Baghdad during 2022. J Fac Med Baghdad. 2024;66:45-50. https://doi.org/10.32007/jfacmedbagdad.2162

Lin Y, Song Y, Zhang Y, Shi M, Hou A, Han S. NFAT signaling dysregulation in cancer: Emerging roles in cancer stem cells. Biomed Pharmacother. 2023;165:115167. https://doi.org/10.1016/j.biopha.2023.115167

Rasheed RA, Al-Abassi HM. TGF-BETA3 (gene expression) as a new biological marker for diagnosing the gastric and colorectal cancer. Biochem Cell Arch. 2021;21:1539-43. http://dx.doi.org/10.13140/RG.2.2.29988.81281

Gounou C, Bouvet F, Liet B, Prouzet-Mauléon V, d'Agata L, Harté E, et al. Annexin-A5 and annexin-A6 silencing prevents metastasis of breast cancer cells in zebrafish. Biol Cell. 2023;115(6):e202200110. https://doi.org/10.1111/boc.202200110

Khalifa MF. Impact of psychological distress in women upon coping with breast cancer. Iraqi Nat J Nurs Spec. 2022;35:82-87. https://doi.org/10.58897/injns.v35i1.565

ALAbady AA, Al-Majidi SMH. Preparation of some new pyrazine and triazine derivatives and study of their antimicrobial and anticancer activities. Iraqi J Sci. 2024;65:2357-72. https://doi.org/10.24996/ijs.2024.65.5.1

Al Shami MA, Saud AM. Assessing gene expression of factor XIII-A1 in Iraqi patients with FXIII deficiency. J Biosc Appl Res. 2024;10(1):103-10. https://doi.org/10.21608/jbaar.2024.268467.1038

Ismael AK, Alabassi HM. PD-1 and NFATc1 as promising immunotherapy for SLE patients. J Popul Therap Clin Pharmacol. 2023;30:260-66. https://doi.org/10.47750/jptcp.2023.30.05.025

Pavitra E, Kancharla J, Gupta VK, Prasad K, Sung JY, Kim J, et al. The role of NF-κB in breast cancer initiation, growth, metastasis, and resistance to chemotherapy. Biomed Pharmacother. 2023;163:1-14. https://doi.org/10.1016/j.biopha.2023.114822

Ma Q, Hao S, Hong W, Tergaonkar V, Sethi G, Tian Y, et al. Versatile function of NF-ĸB in inflammation and cancer. Exp Hematol Oncol. 2024;13(1):68. https://doi.org/10.1186/s40164-024-00529-z

Guo Q, Jin Y, Lin M, Zeng C, Zhang J. NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges. Life Sci. 2024;348:122684. https://doi.org/10.1016/j.lfs.2024.122684

Wang SF, Tseng LM, Lee HC. Role of mitochondrial alterations in human cancer progression and cancer immunity. J Biomed Sci. 2023;30(1):61. https://doi.org/10.1186/s12929-023-00956-w

Patil S, Forster T, Reutlinger K, Kopp W, Versemann L, Spitalieri J, et al. Chromatin-independent interplay of NFATc1 and EZH2 in pancreatic cancer. Cells. 2021;10(12):3463. https://doi.org/10.3390/cells10123463

Zhang X, Song W, Gao Y, Zhang Y, Zhao Y, Hao S, et al. The role of tumor metabolic reprogramming in tumor immunity. Int J Mol Sci. 2023;24(24):17422. https://doi.org/10.3390/ijms242417422

Jing J. The relevance, predictability, and utility of annexin A5 for human physiopathology. Int J Mol Sci. 2024;25(5):2865. https://doi.org/10.3390/ijms25052865

Hein T, Krammer PH, Weyd H. Molecular analysis of annexin expression in cancer. BMC Cancer. 2022;22(1):994. https://doi.org/10.1186/s12885-022-10075-8

Lee S, Lee SL, Min B, Oh SC. Prognostic implication of systemic inflammatory markers in young patients with resectable colorectal cancer. Ann Surg Treat Res. 2021;100:25-32. https://doi.org/10.4174/astr.2021.100.1.25

Cruz-Reyes N, Radisky DC. Inflammation, infiltration, and evasion-tumor promotion in the aging breast. Cancers. 2023;15:1836. https://doi.org/10.3390/cancers15061836

Bower JE, Ganz PA, Irwin MR, Cole SW, Carroll J, Kuhlman KR, et al. Acute and chronic effects of adjuvant therapy on inflammatory markers in breast cancer patients. JNCI Cancer Spectr. 2022;6:1-9. https://doi.org/10.1093/jncics/pkac052

El Hagary HM. Study of the serum level of annexin A5 as a marker for hepatocellular carcinoma in hepatitis C virus cirrhosis patients. Afro-Egypt J Infect Endem Dis. 2023;13(3):165-73. https://doi.org/10.21608/aeji.2023.211128.1291

Woodward A, Faria GNF, Harrison RG. Annexin A5 as a targeting agent for cancer treatment. Cancer Lett. 2022;547:215857. https://doi.org/10.1016/j.canlet.2022.215857

Zhu B, Zhang X, Sun S, Fu Y, Xie L, Ai P. NF-κB and neutrophil extracellular traps cooperate to promote breast cancer progression and metastasis. Exp Cell Res. 2021;405:1-12. https://doi.org/10.1016/j.yexcr.2021.112707

Surai PF, Surai A, Earle-Payne K. Silymarin and inflammation: food for thoughts. Antioxidants. 2024;13(1):98. https://doi.org/10.3390/antiox13010098

Ghasemi M, Reiazi N, Behzad-Behbahani A, Takhshid MA. Annexin-A5 overexpression increases sensitivity of MCF-7 and MCF-7/ADR cells to epirubicin. Avicenna J Med Biotechnol. 2023;16:34-9. https://doi.org/10.18502/ajmb.v16i1.14169

Liu X, Wang L, Duan C, Rong Y, Liang Y, Zhu QX, et al. Daurisoline inhibits proliferation, induces apoptosis, and enhances TRAIL sensitivity of breast cancer cells by upregulating DR5. Cell Biol Int. 2024;48:951-63. https://doi.org/10.1002/cbin.12162

Hasani S, Fathabadi F, Saeidi S, Mohajernoei P, Hesari Z. The role of NFATc1 in the progression and metastasis of prostate cancer: a review on the molecular mechanisms and signaling pathways. Cell Biol Int. 2023;47:1895-904. https://doi.org/10.1002/cbin.12094

Lv F, Qin J, Kong S, Pan L, Ding R. MicroRNA-506 ameliorates breast cancer-induced osteolytic bone metastasis via the NFATc-1 signaling pathway. J Biochem Mol Toxicol. 2022;36:1-10. https://doi.org/10.1002/jbt.23156

Abidalkareem A, Ibrahim AK, Abd M, Rehman O, Zhuang H. Identification of gene expression in different stages of breast cancer with machine learning. Cancers. 2024;16:1-16. https://doi.org/10.3390/cancers16101864

Ren C, Han X, Lu C, Yang T, Qiao P, Sun Y, et al. Ubiquitination of NF-κB p65 by FBXW2 suppresses breast cancer stemness, tumorigenesis, and paclitaxel resistance. Cell Death Differ. 2022;29(2):381-92. https://doi.org/10.1038/s41418-021-00862-4

Zuo X, Zhao X, Zhang X, Li Q, Jiang X, Huang S, et al. PTPN20 promotes metastasis through activating NF-κB signaling in triple-negative breast cancer. Breast Cancer Res. 2024;26(1):155. https://doi.org/10.1186/s13058-024-01910-w

Yang D, Chen H, Zhou Z, Guo J. ANXA5 predicts prognosis and immune response and mediates proliferation and migration in head and neck squamous cell carcinoma. Gene. 2024;931:148867. https://doi.org/10.1016/j.gene.2024.148867

Pimentel JM, Zhou JY, Wu GS. The role of TRAIL in apoptosis and immunosurveillance in cancer. Cancers (Basel). 2023;15(10):2752. https://doi.org/10.3390/cancers15102752

Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2018;20:19-33. https://doi.org/10.1038/s41583-018-0093-1

Kundu M, Greer YE, Dine JL, Lipkowitz S. Targeting TRAIL death receptors in triple-negative breast cancers: challenges and strategies for cancer therapy. Cells. 2022;11:1-37. https://doi.org/10.3390/cells11233717

DOI: https://doi.org/10.46903/gjms/23.1.1866